Cipla has been granted a patent for a long-term storage stable multi-dose pharmaceutical liquid formulation containing pemetrexed for lung cancer treatment. The formulation includes specific ingredients and must meet purity standards after six months of storage. GlobalData’s report on Cipla gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cipla Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cipla, Peptide pharmacophores was a key innovation area identified from patents. Cipla's grant share as of April 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11931362B2) discloses a long-term storage multi-dose pharmaceutical liquid formulation containing pemetrexed or its salt, an antioxidant, a preservative, and a buffering agent. The formulation, stored for six months at specified conditions, must contain no more than 1.0% total impurity. The antioxidant options include monothioglycerol, L-cysteine, and others, while preservatives like benzyl alcohol or m-cresol are included in specific amounts. The buffering agent, such as sodium citrate, is crucial for stability and must be present within a defined range.

Moreover, the patent details methods for producing the formulation and its application in treating malignant pleural mesothelioma or non-squamous, non-small cell lung cancer. The formulation can be combined with cisplatin or carboplatin with pembrolizumab for enhanced therapeutic effects. Additionally, a kit containing the pharmaceutical formulation in vials along with storage and usage instructions is also part of the patent. The formulation's pH, presence of pemetrexed in specific concentrations, and absence of amino acids are highlighted features, making it suitable for parenteral administration and long-term storage.

To know more about GlobalData’s detailed insights on Cipla, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies